JPS57176916A - Novel thiolated polypeptide derived from tetanus toxin fragment, preparation and application - Google Patents

Novel thiolated polypeptide derived from tetanus toxin fragment, preparation and application

Info

Publication number
JPS57176916A
JPS57176916A JP57007770A JP777082A JPS57176916A JP S57176916 A JPS57176916 A JP S57176916A JP 57007770 A JP57007770 A JP 57007770A JP 777082 A JP777082 A JP 777082A JP S57176916 A JPS57176916 A JP S57176916A
Authority
JP
Japan
Prior art keywords
preparation
application
tetanus toxin
polypeptide derived
toxin fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP57007770A
Other languages
English (en)
Inventor
Bitsuchini Berunaaru
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut Pasteur de Lille
Original Assignee
Institut Pasteur de Lille
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut Pasteur de Lille filed Critical Institut Pasteur de Lille
Publication of JPS57176916A publication Critical patent/JPS57176916A/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6829—Bacterial toxins, e.g. diphteria toxins or Pseudomonas exotoxin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/34—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Corynebacterium (G)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y10S530/825—Bacteria

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Mycology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
JP57007770A 1981-01-22 1982-01-22 Novel thiolated polypeptide derived from tetanus toxin fragment, preparation and application Pending JPS57176916A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR8101176A FR2498192A2 (fr) 1981-01-22 1981-01-22 Nouveau compose polypeptidique thiole provenant d'un fragment de la toxine tetanique, son procede d'obtention et ses applications

Publications (1)

Publication Number Publication Date
JPS57176916A true JPS57176916A (en) 1982-10-30

Family

ID=9254407

Family Applications (1)

Application Number Title Priority Date Filing Date
JP57007770A Pending JPS57176916A (en) 1981-01-22 1982-01-22 Novel thiolated polypeptide derived from tetanus toxin fragment, preparation and application

Country Status (7)

Country Link
US (1) US4479940A (ja)
EP (1) EP0057140B1 (ja)
JP (1) JPS57176916A (ja)
CA (1) CA1182811A (ja)
DE (1) DE3264703D1 (ja)
ES (2) ES8306714A1 (ja)
FR (1) FR2498192A2 (ja)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59116229A (ja) * 1982-12-24 1984-07-05 Teijin Ltd 細胞毒性複合体を活性成分とする癌治療用剤およびその製造法
JPS59116232A (ja) * 1982-12-24 1984-07-05 Teijin Ltd 細胞毒性複合体及びその製造法
US4664911A (en) * 1983-06-21 1987-05-12 Board Of Regents, University Of Texas System Immunotoxin conjugates employing toxin B chain moieties
IL69558A (en) * 1983-08-23 1988-06-30 Yeda Res & Dev Synthetic cholera vaccine
US4666884A (en) * 1984-04-10 1987-05-19 New England Deaconess Hospital Method of inhibiting binding of von Willebrand factor to human platelets and inducing interaction of platelets with vessel walls
CA1314245C (en) * 1984-05-23 1993-03-09 Franz Jansen Process for the preparation of conjugates in which a monovalent carboxylic ionophore is associated by means of a covalent bond with a macromolecule, which are useful as immunotoxin potentiators
FR2567521B1 (fr) * 1984-07-13 1987-01-02 Sanofi Sa Nouveaux ionophores actives
US6022950A (en) * 1984-06-07 2000-02-08 Seragen, Inc. Hybrid molecules having translocation region and cell-binding region
US5668255A (en) * 1984-06-07 1997-09-16 Seragen, Inc. Hybrid molecules having translocation region and cell-binding region
FR2575160B1 (fr) * 1984-12-21 1987-03-20 Sanofi Sa Composes ionophores carboxyliques monovalents
US4762710A (en) * 1986-06-16 1988-08-09 The United States Of America As Represented By The Department Of Health And Human Services Novel method of preparing toxoid by oxidation and metal ions
US5084559A (en) * 1987-03-27 1992-01-28 Repligen Corporation Protein a domain mutants
US5601826A (en) * 1989-06-30 1997-02-11 The United States Of America As Represented By The Department Of Health And Human Services Peptide which produces protective immunity against tetanus
GB9020075D0 (en) * 1990-09-14 1990-10-24 Filler Aaron G Contrast agents for magnetic resonance imaging of axonal transport
US5948384A (en) * 1990-09-14 1999-09-07 Syngenix Limited Particulate agents
US6919067B2 (en) 1991-09-13 2005-07-19 Syngenix Limited Compositions comprising a tissue glue and therapeutic agents
US5716614A (en) * 1994-08-05 1998-02-10 Molecular/Structural Biotechnologies, Inc. Method for delivering active agents to mammalian brains in a complex with eicosapentaenoic acid or docosahexaenoic acid-conjugated polycationic carrier
ES2281135T3 (es) * 1997-08-14 2007-09-16 Institut Pasteur Proteinas hibridas de un toxoide tetanico que migran de forma retrograda y transinaptica al snc.
US20100081197A1 (en) * 1997-08-14 2010-04-01 Sylvie Roux In vivo modulation of neuronal transport
US7923015B2 (en) * 1997-08-14 2011-04-12 Institut Pasteur Methods for direct visualization of active synapses
US7923216B2 (en) 1997-08-14 2011-04-12 Institut Pasteur In vivo modulation of neuronal transport
US6258774B1 (en) * 1998-03-19 2001-07-10 University Of Medicine And Dentistry Of New Jersey Carrier for in vivo delivery of a therapeutic agent
GB0112687D0 (en) * 2001-05-24 2001-07-18 Microbiological Res Authority Pharmaceutical use of secreted bacterial effector proteins
US20070092449A1 (en) * 2005-04-05 2007-04-26 Rafael Vazquez-Martinez Methods for direct visualization of active synapses
ES2332628B1 (es) 2007-10-05 2011-01-24 Universidad De Zaragoza Uso de la secuencia codificante del dominio carboxilo terminal de la cadena pesada de la toxina tetanica como medicamento.

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2938023A (en) * 1957-04-17 1960-05-24 Hoechst Ag Manufacture of glutathione containing mercapto groups
US3171831A (en) * 1961-02-14 1965-03-02 Schwarz Biores Inc Thiolation of proteins by reaction with homocysteine thiolactone in the presence of tertiary amine
DE1617880A1 (de) * 1966-10-06 1971-07-22 Karl Dr Med Theurer Verfahren zur Gewinnung von organotropen,bioaktiven Wirkstoffen,insbesondere von Arzneimitteln
DE2355094C3 (de) * 1973-11-03 1979-05-23 Behringwerke Ag, 3550 Marburg Verfahren zur Herstellung eines Tetanus-Impfstoffs
IN140168B (ja) * 1974-10-14 1976-09-25 All India Inst Med
JPS5272284A (en) * 1975-12-12 1977-06-16 Dainippon Pharmaceutical Co Enzymeeimmunoassay reagent
JPS5341420A (en) * 1976-09-29 1978-04-14 Mochida Pharm Co Ltd Immunochemically measuring methoa of hapten
US4315031A (en) * 1977-09-01 1982-02-09 Science Union Et Cie Thiosubstituted amino acids
FR2470773B1 (ja) * 1979-11-28 1983-01-28 Pasteur Institut
US4284624A (en) * 1980-05-02 1981-08-18 E. R. Squibb & Sons, Inc. Mixed disulfides

Also Published As

Publication number Publication date
FR2498192B2 (ja) 1983-09-09
US4479940A (en) 1984-10-30
ES508935A0 (es) 1983-06-01
ES519456A0 (es) 1983-11-01
DE3264703D1 (en) 1985-08-22
ES8306714A1 (es) 1983-06-01
EP0057140A2 (fr) 1982-08-04
EP0057140B1 (fr) 1985-07-17
EP0057140A3 (en) 1982-08-25
FR2498192A2 (fr) 1982-07-23
CA1182811A (en) 1985-02-19
ES8400736A1 (es) 1983-11-01

Similar Documents

Publication Publication Date Title
JPS57176916A (en) Novel thiolated polypeptide derived from tetanus toxin fragment, preparation and application
ZA881769B (en) Recombinant ricin toxin fragements
DK565882A (da) Interferonpraeparater og fremgangsmaade til fremstilling heraf
EP0171434A4 (en) CROSSLINKING AGENTS AND THEIR PRODUCTION METHOD.
EP0182921A4 (en) GAS SENSOR.
HUT41836A (en) Process for preparing monoclonal antibodies cross-reactive and cross-protecting against p. aeruginosa serotypes
DE3063169D1 (en) Beta-galactosyl-umbelliferone-labeled protein and polypeptide conjugates, and n-substituted 7-beta-galactosylcumarin-3-carboxamides
EP0218717A4 (en) RECOMBINANT INHIBIN.
NO855026L (no) Aminoacyllabdaner og fremgangsmaate til fremstilling derav.
DK132486D0 (da) Forbedret antibiotikabundet protese, og fremgangsmaade til dens fremstilling
DE3581337D1 (en) Peptide.
DE3582361D1 (en) Farbphotographisches material.
HK63795A (en) Antibiotic polypeptide, process for its preparation and its use
EP0134246A4 (en) PROSTACYCLINE AND THEIR PRODUCTION PROCESS.
DE3160780D1 (en) 2,3-dichloro-2-trifluoromethyl-1,1,1,3,4,4,5,5,5-nonafluoropentane and process for its preparation
NO853400L (no) Polypeptidvaksiner.
GB2146325B (en) 16-fluoro-16,17-didehydro prostanoids and process for their preparation
GB8610243D0 (en) Antigens
GB2084158B (en) Peptide and production thereof
NO156095C (no) Dekorativt beleggingsmateriale og fremgangsmaate til dets fremstilling.
EP0177583A4 (en) PEPTIDE VACCINE OR DIAGNOSTIC, AND POLYPEPTIDE FOR USE THEREOF.
EP0202260A4 (en) IMPROVED ANTIQUE COMPOSITION.
IL69531A (en) Antibodies against bacterial peptidoglycans,their preparation and determination
ZA858034B (en) Antigens
NZ223624A (en) Peptide immunogen from streptococcus mutans, vaccines and antibodies